Author(s): Kontoyiannis D, Lewis R
Zygomycosis is an increasingly common infection in immunocompromised patients. Advances in the understanding of Zygomycetes pathobiology and the introduction of new drugs with improved activity and tolerability for treatment of zygomycosis have improved the prospects of effectively controlling this devastating infection. Further reductions in mortality will require improved diagnostic and novel therapeutic approaches for this group of aggressive opportunistic molds.
Referred From: https://pubmed.ncbi.nlm.nih.gov/16984870/
Author(s): Maertens J, Demuynck H, Verbeken EK, Zachée P, Verhoef GEG,et al.
Author(s): Casqueiro J, Alves C
Author(s): Mitchell SJ, Gray J, Morgan ME, Hocking MD, Durbin GM, et al.
Author(s): Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA,et al.
Author(s): Bonifaz A, Tirado-Sanchez A, Calderon L, Romero-Cabello R, Kassack J,et al.
Author(s): Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP, et al.
Author(s): Mysheika, Williams L, Lauren A,Burwell, Salisbury D , et al.
Author(s): Tragiannidis A, Groll AH